TBC1 domain family member 4Genealiases: AS160 · NIDDM5
Q-omics provides the consensus-scored TBC1D4 profile across patient tissues and cancer cell-line models. TBC1D4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TBC1D4 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, TBC1D4 RNA expression shows 18,940 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where TBC1D4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBC1D4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBC1D4 survival associations across molecular data types. TBC1D4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBC1D4 RNA expression–survival associations across cancer types. High TBC1D4 expression shows unfavorable associations in UVM and LIHC, but favorable associations in KIRC, HNSC, KIRP and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TBC1D4 RNA expression.
This table summarizes TBC1D4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TBC1D4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBC1D4 shows lower tumor expression in KIRC, THCA, LUAD, UCEC and BRCA and higher tumor expression in COAD. The KIRC box plot shows higher TBC1D4 RNA expression in normal versus tumor tissue (log2 FC = −1.473, t-test p < 0.001).
This table shows molecular features associated with TBC1D4 in patient tissues and cancer cell lines. In patient samples, TBC1D4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TBC1D4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
